The Efficacy and Safety of DOACs Versus LMWH for Cancer-associated Thrombosis: A Systematic Review and Meta-analysis

Overview

Journal Eur J Haematol

Specialty Hematology

Date 2020 May 23

PMID 32441350

Citations 6

Authors

Derrick L Tao

Sven R Olson

Thomas G DeLoughery

Joseph J Shatzel

Affiliations

Soon will be listed here.

Citing Articles

The Role of Direct Oral Anticoagulants in the Treatment of Cancer-Associated Venous Thromboembolism: Review by Middle East and North African Experts.

Bazarbashi S, El Zawahry H, Owaidah T, AlBader M, Warsi A, Marashi M J Blood Med. 2024; 15:171-189.

PMID: 38686358 PMC: 11057512. DOI: 10.2147/JBM.S411520.

Smart thrombosis inhibitors without bleeding side effects via charge tunable ligand design.

La C, Smith S, Vappala S, Adili R, Luke C, Abbina S Nat Commun. 2023; 14(1):2177.

PMID: 37100783 PMC: 10133246. DOI: 10.1038/s41467-023-37709-0.

Safe and effective treatment of venous Thromboembolism associated with Cancer: focus on direct Oral Anticoagulants in Asian patients.

Lee L, Danchaivijitr P, Uaprasert N, Gill H, Sacdalan D, Ho G Exp Hematol Oncol. 2022; 11(1):79.

PMID: 36303259 PMC: 9615183. DOI: 10.1186/s40164-022-00331-9.

Direct oral anticoagulants versus low-molecular-weight heparins for the treatment of acute venous thromboembolism in patients with gastrointestinal cancer: a systematic review and meta-analysis.

Rungjirajittranon T, Owattanapanich W, Chinthammitr Y, Ruchutrakool T, Suwanawiboon B Thromb J. 2022; 20(1):41.

PMID: 35902879 PMC: 9330678. DOI: 10.1186/s12959-022-00399-7.

Incidence of venous thromboembolism in advanced lung cancer and efficacy and safety of direct oral anticoagulants: a multicenter, prospective, observational study (Rising-VTE/NEJ037 study).

Tsubata Y, Hotta T, Hamai K, Furuya N, Yokoyama T, Saito R Ther Adv Med Oncol. 2022; 14:17588359221110171.

PMID: 35898966 PMC: 9310216. DOI: 10.1177/17588359221110171.

References

Li A, Garcia D, Lyman G, Carrier M . Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis. Thromb Res. 2018; 173:158-163. PMC: 6119655. DOI: 10.1016/j.thromres.2018.02.144. View

Khorana A . Venous thromboembolism and prognosis in cancer. Thromb Res. 2010; 125(6):490-3. PMC: 2878879. DOI: 10.1016/j.thromres.2009.12.023. View

Mai V, Tanguay V, Guay C, Bertoletti L, Magnan S, Turgeon A . DOAC compared to LMWH in the treatment of cancer related-venous thromboembolism: a systematic review and meta-analysis. J Thromb Thrombolysis. 2020; 50(3):661-667. DOI: 10.1007/s11239-020-02055-1. View

Khorana A, Noble S, Lee A, Soff G, Meyer G, OConnell C . Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH. J Thromb Haemost. 2018; 16(9):1891-1894. DOI: 10.1111/jth.14219. View

Agnelli G, Becattini C, Meyer G, Munoz A, Huisman M, Connors J . Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. N Engl J Med. 2020; 382(17):1599-1607. DOI: 10.1056/NEJMoa1915103. View

Thapa N, Shatzel J, DeLoughery T, Olson S . Direct oral anticoagulants in gastrointestinal malignancies: is the convenience worth the risk?. J Gastrointest Oncol. 2019; 10(4):807-809. PMC: 6657330. DOI: 10.21037/jgo.2019.02.07. View

Fuentes H, McBane 2nd R, Wysokinski W, Tafur A, Loprinzi C, Murad M . Direct Oral Factor Xa Inhibitors for the Treatment of Acute Cancer-Associated Venous Thromboembolism: A Systematic Review and Network Meta-analysis. Mayo Clin Proc. 2019; 94(12):2444-2454. DOI: 10.1016/j.mayocp.2019.05.035. View

Lee A, Levine M, Baker R, Bowden C, Kakkar A, Prins M . Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003; 349(2):146-53. DOI: 10.1056/NEJMoa025313. View

Steffel J, Verhamme P, Potpara T, Albaladejo P, Antz M, Desteghe L . The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018; 39(16):1330-1393. DOI: 10.1093/eurheartj/ehy136. View

10.

Young A, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C . Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D). J Clin Oncol. 2018; 36(20):2017-2023. DOI: 10.1200/JCO.2018.78.8034. View

11.

Rossel A, Robert-Ebadi H, Combescure C, Grosgurin O, Stirnemann J, Addeo A . Anticoagulant therapy for acute venous thrombo-embolism in cancer patients: A systematic review and network meta-analysis. PLoS One. 2019; 14(3):e0213940. PMC: 6428324. DOI: 10.1371/journal.pone.0213940. View

12.

Witt D, Nieuwlaat R, Clark N, Ansell J, Holbrook A, Skov J . American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. Blood Adv. 2018; 2(22):3257-3291. PMC: 6258922. DOI: 10.1182/bloodadvances.2018024893. View

13.

Lee A, Kamphuisen P, Meyer G, Bauersachs R, Janas M, Jarner M . Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial. JAMA. 2015; 314(7):677-686. DOI: 10.1001/jama.2015.9243. View

14.

McBane 2nd R, Wysokinski W, Le-Rademacher J, Zemla T, Ashrani A, Tafur A . Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial. J Thromb Haemost. 2019; 18(2):411-421. DOI: 10.1111/jth.14662. View

15.

Raskob G, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D . Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. N Engl J Med. 2017; 378(7):615-624. DOI: 10.1056/NEJMoa1711948. View